Furthermore, the study of Olaussen et al. (9) demonstrated that the benefit of adjuvant chemotherapy with cisplatin was lost when there was a high expression of ERCC1 in the small-cell lung cancer tumor. Here, ERCC1 is linked to neoplasm.